The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma

The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma

Ahmadzadehfar H^{1, 2} ; Aryana K³ ; Pirayesh E² ; Farzanehfar S⁴ ; Assadi M⁵ ; Fallahi B⁶ ; Shafiei B² ; Ayati N³ ; Amoui M²

Show Affiliations

1. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
2. Department of Nuclear Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
5. Persian Gulf Nuclear Medicine Research Center, Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
6. Research Centre for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Nuclear Medicine Published:2018

Abstract

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with continuously increasing interest and use worldwide. This guideline is intended to assist nuclear medicine physicians in evaluating and managing patients with mRCPC for whom radioligand therapy (RLT) using 177Lu-PSMA is a promising treatment option. In addition, more information could be provided by subsequent investigative studies in the field of RLT. © 2018 Tehran University of Medical Sciences. All rights reserved.

Related Docs

View other Related Docs

1. Historical Review of Pharmacological Development and Dosimetry of Psma-Based Theranostics for Prostate Cancer, Journal of Radioanalytical and Nuclear Chemistry (2019)

2. Factors Predicting the Early Biochemical Response to [177Lu]Lu-Psma Therapy in Patients With Metastatic Castration Resistant Prostate Cancer, Iranian Journal of Nuclear Medicine (2022)

3. Design, Synthesis, Radiolabeling and Biological Evaluation of New Urea-Based Peptides Targeting Prostate Specific Membrane Antigen, Bioorganic Chemistry (2020)

4. Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy With [177Lu]Lu-Psma in Metastatic Castrate-Resistant Prostate Cancer: A Review, European Journal of Nuclear Medicine and Molecular Imaging (2021)

5. Predictive and Prognostic Potential of Pretreatment 68Ga-Psma Pet Tumor Heterogeneity Index in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With 177Lu-Psma, Frontiers in Oncology (2022)

6. Therapeutic Outcomes Of177lu-Psma Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study, Asia Oceania Journal of Nuclear Medicine and Biology (2023)

7. Prognostic Significance of Baseline Clinical and [68Ga]Ga-Psma Pet Derived Parameters on Biochemical Response, Overall Survival, and Psa Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Undergoing [177Lu]Lu-Psma Therapy, Nuklearmedizin - NuclearMedicine (2024)

8. Passive-Specific Immunotherapy With Monoclonal Antibodies for Prostate Cancer: A Systematic Review, Journal of Oncology Pharmacy Practice (2019)

Experts (# of related papers)

View all Related Experts

Reyhaneh Manafi-Farid (5)

Saeed Farzanefar (3)

Style	Citing Format
MLA	Ahmadzadehfar H, et al.. "The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma." Iranian Journal of Nuclear Medicine, vol. 26, no. 1, 2018, pp. 2-8.
APA	Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, Shafiei B, Ayati N, Amoui M (2018). The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma. Iranian Journal of Nuclear Medicine, 26(1), 2-8.
Chicago	Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, Shafiei B, Ayati N, Amoui M. "The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma." Iranian Journal of Nuclear Medicine 26, no. 1 (2018): 2-8.
Harvard	Ahmadzadehfar H et al. (2018) 'The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma', Iranian Journal of Nuclear Medicine, 26(1), pp. 2-8.
Vancouver	Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, et al.. The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma. Iranian Journal of Nuclear Medicine. 2018;26(1):2-8.
BibTex	@article{ author = {Ahmadzadehfar H and Aryana K and Pirayesh E and Farzanehfar S and Assadi M and Fallahi B and Shafiei B and Ayati N and Amoui M}, title = {The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma}, journal = {Iranian Journal of Nuclear Medicine}, volume = {26}, number = {1}, pages = {2-8}, year = {2018} }
RIS	TY - JOUR AU - Ahmadzadehfar H AU - Aryana K AU - Pirayesh E AU - Farzanehfar S AU - Assadi M AU - Fallahi B AU - Shafiei B AU - Ayati N AU - Amoui M TI - The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma JO - Iranian Journal of Nuclear Medicine VL - 26 IS - 1 SP - 2 EP - 8 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract